NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
DescriptionNewLimit is seeking an experienced cell and molecular biologist with a background in functional genomics to join our Epigenetic Editing team. Our therapies restore cell function by reprogramming the epigenome with both natural transcription factors and programmable editors. You will be instrumental to the discovery and development process for this new class of medicines.
As a member of our team, you will:
- Run the largest reprogramming screens in the world in collaboration with our Single Cell Genomics and Predictive Modeling teams
- Develop methods for the construction, delivery, and control of epigenetic reprogramming payloads for single cell screens in primary mammalian cells
- Build and deploy molecular tools at a massive scale
- Design and implement functional genomics screens to measure the effect of epigenetic reprogramming on the molecular and functional state of primary mammalian cells
- Contribute to the design and formulation of therapeutic molecules (e.g. mRNA synthesis and optimization, lipid nanoparticle formulation)
- Ph.D. in molecular biology, cell biology, or a related field or equivalent industry experience (5+ years)
- Experience with functional genomics approaches for pooled or arrayed screening (e.g. one of: CRISPR-Cas pooled fitness screens, gene expression perturbation profiling, Perturb/CROP-seq, or similar methods)
- Experience with molecular cloning, next-generation sequencing, and associated molecular biology methods
- Experience with in vitro and in vivo transgenic delivery methods for mammalian cells (at least one of: lentivirus, AAV, AdV, transposition systems, lipid nanoparticles, or similar)
- Experience with epigenetic reprogramming methods using transcription factors for cell fate engineering or CRISPR-Cas tools for targeted epigenetic editing
- Experience working with primary cells and tissue samples
- Experience with single cell genomics methods
- Python programming and Unix workflow management skills
- Therapeutics development experience
NewLimit offers generous benefits to ensure our team can focus on our mission:
- Health, dental, and vision insurance
- 401(k) with company match
- Paid parental leave
- Industry-leading paid time off (PTO) — 20 days/year for all employees + holidays
- Meals and snacks on-site
Salary Range: $130,000 to $170,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.
NewLimit South San Francisco, California, USA Office
South San Francisco, CA, United States, 94080
Similar Jobs
What you need to know about the San Francisco Tech Scene
Key Facts About San Francisco Tech
- Number of Tech Workers: 365,500; 13.9% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Google, Apple, Salesforce, Meta
- Key Industries: Artificial intelligence, cloud computing, fintech, consumer technology, software
- Funding Landscape: $50.5 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Sequoia Capital, Andreessen Horowitz, Bessemer Venture Partners, Greylock Partners, Khosla Ventures, Kleiner Perkins
- Research Centers and Universities: Stanford University; University of California, Berkeley; University of San Francisco; Santa Clara University; Ames Research Center; Center for AI Safety; California Institute for Regenerative Medicine

